Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T8MA
|
|||
| Former ID |
DIB005567
|
|||
| Drug Name |
ATN-224
|
|||
| Synonyms |
Angiogenesis inhibitor, Attenuon; Superoxide dismutase 1 inhibitor, Attenuon
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | |
| Company |
University of Michigan
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H30MoN2O2S4
|
|||
| Canonical SMILES |
C[N+](C)(C)CCO.C[N+](C)(C)CCO.[SH-].[SH-].S=[Mo]=S
|
|||
| InChI |
1S/2C5H14NO.Mo.2H2S.2S/c2*1-6(2,3)4-5-7;;;;;/h2*7H,4-5H2,1-3H3;;2*1H2;;/q2*+1;;;;;/p-2
|
|||
| InChIKey |
FSWNJZRQQVVVJT-UHFFFAOYSA-L
|
|||
| CAS Number |
CAS 649749-10-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Superoxide dismutase Cu-Zn (SOD Cu-Zn) | Target Info | Inhibitor | [2] |
| BioCyc | Reactive oxygen species degradation | |||
| KEGG Pathway | Peroxisome | |||
| Amyotrophic lateral sclerosis (ALS) | ||||
| Huntington's disease | ||||
| Prion diseases | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathwhiz Pathway | Degradation of Superoxides | |||
| Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | |||
| FOXA1 transcription factor network | ||||
| Reactome | Platelet degranulation | |||
| Detoxification of Reactive Oxygen Species | ||||
| WikiPathways | Oxidative Stress | |||
| Copper homeostasis | ||||
| Detoxification of Reactive Oxygen Species | ||||
| Nifedipine Activity | ||||
| Amyotrophic lateral sclerosis (ALS) | ||||
| Dopamine metabolism | ||||
| AGE/RAGE pathway | ||||
| Folate Metabolism | ||||
| Vitamin B12 Metabolism | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00405574) Study of ATN-224 in Patients With Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.